<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "3: Additional ", fill: "#ec5800"},
{source: "3: Additional ", target: "3: immaterial may also impair", fill: "#ec5800"},
{source: "3: immaterial may also impair", target: "3: operations", fill: "#ec5800"},
{source: "3: Additional ", target: "8: Accordingly ", fill: "#c66"},
{source: "8: Accordingly ", target: "8: customers generally", fill: "#c66"},
{source: "8: customers generally", target: "8: relatively long", fill: "#c66"},
{source: "8: relatively long", target: "8: significant", fill: "#c66"},
{source: "8: significant", target: "8: typically derived from sales", fill: "#c66"},
{source: "8: Accordingly ", target: "31: competitors", fill: "#ff0038"},
{source: "31: competitors", target: "31: significantly", fill: "#ff0038"},
{source: "31: significantly", target: "31: competition", fill: "#ff0038"},
{source: "31: competitors", target: "35: competitors", fill: "#2f4f4f"},
{source: "35: competitors", target: "35: technologies", fill: "#2f4f4f"},
{source: "35: technologies", target: "35: developments", fill: "#2f4f4f"},
{source: "35: developments", target: "35: development promotion", fill: "#2f4f4f"},
{source: "35: development promotion", target: "35: products which could impair sales", fill: "#2f4f4f"},
{source: "35: competitors", target: "67: longterm supply agreements", fill: "#560319"},
{source: "67: longterm supply agreements", target: "67: agreements", fill: "#560319"},
{source: "67: agreements", target: "67: Contents ", fill: "#560319"},
{source: "67: Contents ", target: "67: particular consumable", fill: "#560319"},
{source: "67: particular consumable", target: "67: subassembly", fill: "#560319"},
{source: "67: longterm supply agreements", target: "74: may encounter manufacturing", fill: "#fdee00"},
{source: "74: may encounter manufacturing", target: "74: assembly problems", fill: "#fdee00"},
{source: "74: assembly problems", target: "74: delays which could", fill: "#fdee00"},
{source: "74: delays which could", target: "74: lost revenues", fill: "#fdee00"},
{source: "74: may encounter manufacturing", target: "88: consistently manufacture", fill: "#ca2c92"},
{source: "88: consistently manufacture", target: "88: timely basis", fill: "#ca2c92"},
{source: "88: timely basis", target: "88: product sales will", fill: "#ca2c92"},
{source: "88: consistently manufacture", target: "101: reliance on international sales", fill: "#b87333"},
{source: "101: reliance on international sales", target: "101: operations exposes us", fill: "#b87333"},
{source: "101: operations exposes us", target: "101: political social", fill: "#b87333"},
{source: "101: political social", target: "101: economic instability", fill: "#b87333"},
{source: "101: economic instability", target: "101: trade restrictions", fill: "#b87333"},
{source: "101: trade restrictions", target: "101: restrictions", fill: "#b87333"},
{source: "101: restrictions", target: "101: economies outside", fill: "#b87333"},
{source: "101: economies outside", target: "101: United States ", fill: "#b87333"},
{source: "101: United States ", target: "101: regulatory requirements", fill: "#b87333"},
{source: "101: regulatory requirements", target: "101: sell into particular jurisdictions", fill: "#b87333"},
{source: "101: sell into particular jurisdictions", target: "101: export license requirements", fill: "#b87333"},
{source: "101: export license requirements", target: "101: difficulties", fill: "#b87333"},
{source: "101: difficulties", target: "101: staffing managing", fill: "#b87333"},
{source: "101: staffing managing", target: "101: geographically disparate operations", fill: "#b87333"},
{source: "101: geographically disparate operations", target: "101: effective communications with employees", fill: "#b87333"},
{source: "101: effective communications with employees", target: "101: customers due", fill: "#b87333"},
{source: "101: customers due", target: "101: distance language", fill: "#b87333"},
{source: "101: distance language", target: "101: cultural barriers", fill: "#b87333"},
{source: "101: cultural barriers", target: "101: disruptions", fill: "#b87333"},
{source: "101: disruptions", target: "101: international transport", fill: "#b87333"},
{source: "101: international transport", target: "101: intellectual property rights", fill: "#b87333"},
{source: "101: intellectual property rights", target: "101: particularly", fill: "#b87333"},
{source: "101: particularly", target: "101: proprietary rights", fill: "#b87333"},
{source: "101: proprietary rights", target: "101: United States ", fill: "#b87333"},
{source: "101: United States ", target: "101: enforcing agreements through nonUS legal systems", fill: "#b87333"},
{source: "101: enforcing agreements through nonUS legal systems", target: "101: longer payment cycles", fill: "#b87333"},
{source: "101: longer payment cycles", target: "101: collecting receivables", fill: "#b87333"},
{source: "101: collecting receivables", target: "101: potentially adverse tax consequences", fill: "#b87333"},
{source: "101: reliance on international sales", target: "108: pharmaceutical", fill: "#faebd7"},
{source: "108: pharmaceutical", target: "108: biotechnology", fill: "#faebd7"},
{source: "108: biotechnology", target: "108: industries", fill: "#faebd7"},
{source: "108: pharmaceutical", target: "START_HERE", fill: "#faebd7"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Construction and Engineering</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Life Sciences Tools and Services</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Demonstrate</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Defy norms</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_figures">Significant figures</a></td>
      <td>Significant figures (also known as the significant digits, precision or resolution) of a number in positional notation are digits in the number that are reliable and necessary to indicate the quantity of something.\nIf a number expressing the result of a measurement (e.g., length, pressure, volume, or mass) has more digits than the number of digits allowed by the measurement resolution, then only as many digits as allowed by the measurement resolution are reliable, and so only these can be significant figures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_other">Significant other</a></td>
      <td>The term significant other (SO) has different uses in psychology and in colloquial language. Colloquially "significant other" is used as a gender-neutral term for a person's partner in an intimate relationship without disclosing or presuming anything about marital status, relationship status, gender identity, or sexual orientation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bit_numbering">Bit numbering</a></td>
      <td>In computing, bit numbering is the convention used to identify the bit positions in a binary number.\n\n\n== Bit significance and indexing ==\n\nIn computing, the least significant bit (LSB) is the bit position in a binary integer representing the binary 1s place of the integer.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_form">Significant form</a></td>
      <td>Significant form refers to an aesthetic theory developed by English art critic Clive Bell which specified a set of criteria for what qualified as a work of art.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_Others">Significant Others</a></td>
      <td>The term significant other (SO) has different uses in psychology and in colloquial language. Colloquially "significant other" is used as a gender-neutral term for a person's partner in an intimate relationship without disclosing or presuming anything about marital status, relationship status, gender identity, or sexual orientation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Simpsons">The Simpsons</a></td>
      <td>The Simpsons is an American animated sitcom created by Matt Groening for the Fox Broadcasting Company. The series is a satirical depiction of American life, epitomized by the Simpson family, which consists of Homer, Marge, Bart, Lisa, and Maggie.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_Mother">Significant Mother</a></td>
      <td>Significant Mother is an American television sitcom created by Erin Cardillo and Richard Keith. Starring Josh Zuckerman, Nathaniel Buzolic and Krista Allen, it premiered on The CW network on August 3 and ended its run on October 5, 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Internet">Internet</a></td>
      <td>In finance and economics, interest is payment from a borrower or deposit-taking financial institution to a lender or depositor of an amount above repayment of the principal sum (that is, the amount borrowed), at a particular rate. It is distinct from a fee which the borrower may pay the lender or some third party.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competition">Competition</a></td>
      <td>Competition is a rivalry where two or more parties strive for a common goal which cannot be shared: where one's gain is the other's loss (an example of which is a zero-sum game). Competition can arise between entities such as organisms, individuals, economic and social groups, etc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_analysis">Competitor analysis</a></td>
      <td>Competitive analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors. This analysis provides both an offensive and defensive strategic context to identify opportunities and threats.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitors_for_the_Crown_of_Scotland">Competitors for the Crown of Scotland</a></td>
      <td>When the crown of Scotland became vacant in September 1290 on the death of the seven-year-old child Queen Margaret, 13 claimants to the throne came forward. Those with the most credible claims were John Balliol, Robert Bruce, John Hastings and Floris V, Count of Holland.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_Dancing_with_the_Stars_(American_TV_series)_competitors">List of Dancing with the Stars (American TV series) competitors</a></td>
      <td>Dancing with the Stars is an American reality television show in which celebrity contestants and professional dance partners compete to be the best dancers, as determined by the show's judges and public voting. The series first broadcast in 2005, and thirty complete seasons have aired on ABC. During each season, competitors are progressively eliminated on the basis of public voting and scores received from the judges until only a few contestants remain.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_Group">Competitor Group</a></td>
      <td>Competitor Group, Inc. (CGI) is a privately held, for-profit, sports marketing and management company based in Mira Mesa, San Diego, California.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Round-robin_tournament">Round-robin tournament</a></td>
      <td>A round-robin tournament (or all-play-all tournament) is a competition in which each contestant meets every other participant, usually in turn. A round-robin contrasts with an elimination tournament, in which participants are eliminated after a certain number of losses.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/TRIPS_Agreement">TRIPS Agreement</a></td>
      <td>The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) is an international legal agreement between all the member nations of the World Trade Organization (WTO). It establishes minimum standards for the regulation by national governments of different forms of intellectual property (IP) as applied to nationals of other WTO member nations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutical_industry">Pharmaceutical industry</a></td>
      <td>The pharmaceutical industry discovers, develops, produces, and markets drugs or pharmaceutical drugs for use as medications to be administered to patients (or self-administered), with the aim to cure them, vaccinate them, or alleviate symptoms.  Pharmaceutical companies may deal in generic or brand medications and medical devices.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutical_manufacturing">Pharmaceutical manufacturing</a></td>
      <td>Pharmaceutical manufacturing is the process of industrial-scale synthesis of pharmaceutical drugs as part of the pharmaceutical industry.  The process of drug manufacturing can be broken down into a series of unit operations, such as milling, granulation, coating, tablet pressing, and others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Intellectual_property">Intellectual property</a></td>
      <td>Intellectual property (IP) is a category of property that includes intangible creations of the human intellect. There are many types of intellectual property, and some countries recognize more than others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Intellectual_property_infringement">Intellectual property infringement</a></td>
      <td>An intellectual property (IP) infringement is the infringement or violation of an intellectual property right. There are several types of intellectual property rights, such as copyrights, patents, trademarks, industrial designs, and trade secrets.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Indigenous_intellectual_property">Indigenous intellectual property</a></td>
      <td>Indigenous intellectual property is a term used in national and international forums to describe intellectual property that is "collectively owned" by various Indigenous peoples, and by extension, their legal rights to protect specific such property. This property includes cultural knowledge of their groups and many aspects of their cultural heritage and knowledge, including that held in oral history.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Outline_of_intellectual_property">Outline of intellectual property</a></td>
      <td>The following outline is provided as an overview of and topical guide to intellectual property:\nIntellectual property – intangible assets such as musical, literary, and artistic works; discoveries and inventions; and words, phrases, symbols, and designs. Common types of intellectual property rights include copyright, trademarks, patents, industrial design rights, trade dress, and in some jurisdictions trade secrets.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Intellectual_property_in_China">Intellectual property in China</a></td>
      <td>Intellectual property rights (IPRs) have been acknowledged and protected in China since the 1980s. China has acceded to the major international conventions on protection of rights to intellectual property.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medication">Medication</a></td>
      <td>Meditation is a practice in which an individual uses a technique – such as mindfulness, or focusing the mind on a particular object, thought, or activity – to train attention and awareness, and achieve a mentally clear and emotionally calm and stable state.Meditation  is practiced in numerous religious traditions. The earliest records of meditation (dhyana) are found in the Upanishads of Hindu philosophy, and meditation plays a salient role in the contemplative repertoire of Buddhism and Hinduism.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutics">Pharmaceutics</a></td>
      <td>Pharmaceutics is the discipline of pharmacy that deals with the process of turning a new chemical entity (NCE) or old drugs into a medication to be used safely and effectively by patients.  It is also called the science of dosage form design.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Teva_Pharmaceuticals">Teva Pharmaceuticals</a></td>
      <td>Teva Pharmaceutical Industries Ltd. (also known as Teva Pharmaceuticals) is an Israeli multinational pharmaceutical company with headquarters in Petah Tikva, Israel.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutical_code">Pharmaceutical code</a></td>
      <td>Pharmaceutical codes are used in medical classification to uniquely identify medication. They may uniquely identify an active ingredient, drug system (including inactive ingredients and time-release agents) in general, or a specific pharmaceutical product from a specific manufacturer.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Janssen_Pharmaceuticals">Janssen Pharmaceuticals</a></td>
      <td>Janssen Pharmaceuticals is a pharmaceutical company headquartered in Beerse, Belgium, and wholly-owned by Johnson &amp; Johnson. It was founded in 1953 by Paul Janssen.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmacology">Pharmacology</a></td>
      <td>Pharmacology is a branch of medicine, biology and pharmaceutical sciences concerned with drug or medication action, where a drug may be defined as any artificial, natural, or endogenous (from within the body) molecule which exerts a biochemical or physiological effect on the cell, tissue, organ, or organism (sometimes the word pharmacon is used as a term to encompass these endogenous and exogenous bioactive species). More specifically, it is the study of the interactions that occur between a living organism and chemicals that affect normal or abnormal biochemical function.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>MOLECULAR DEVICES CORP      Item 1A   <font color="blue">Risk Factors</font></td>
    </tr>
    <tr>
      <td>Our business faces <font color="blue">significant</font> risks and the <font color="blue">risks described</font> below may not     be the only risks we face</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>risks that we do not know of or that     we currently think are <font color="blue">immaterial may also impair</font> our business <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If any of the events or <font color="blue">circumstances described</font> in the <font color="blue">following risks</font>     actually occurs, our business, <font color="blue">financial condition</font> or results of <font color="blue">operations</font>     could be harmed and the <font color="blue">trading price</font> of our <font color="blue"><font color="blue">common stock</font> <font color="blue">could decline</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Variations </font>in the amount of time it takes for us to sell our products and     <font color="blue">collect accounts receivable</font> and the timing of <font color="blue">customer orders may</font> cause     <font color="blue">fluctuations</font> in our operating results, <font color="blue">which could</font> cause our stock price to     decline</td>
    </tr>
    <tr>
      <td>The timing of <font color="blue">capital equipment purchases by</font> our customers has been and is     expected to continue to be uneven and <font color="blue">difficult</font> to predict</td>
    </tr>
    <tr>
      <td>Our products     represent  <font color="blue">major capital purchases</font> for our customers</td>
    </tr>
    <tr>
      <td>Accordingly, our     <font color="blue">customers <font color="blue">generally</font></font> take a <font color="blue"><font color="blue">relatively</font> long</font> time to evaluate our products,     and a <font color="blue">significant</font> portion of our revenue is <font color="blue">typically <font color="blue">derived from</font> sales</font> of     a small number of <font color="blue">relatively</font> high-priced products</td>
    </tr>
    <tr>
      <td><font color="blue">Purchases </font>are <font color="blue">generally</font>     made by                                         11       _________________________________________________________________    [77]Table of <font color="blue">Contents       </font>purchase  orders  and  not  long-term  contracts</td>
    </tr>
    <tr>
      <td>Delays in receipt of     anticipated orders for our <font color="blue">relatively</font> high-priced products could lead to     substantial  <font color="blue">variability</font> from quarter to quarter</td>
    </tr>
    <tr>
      <td>Furthermore, we have     <font color="blue">historically</font> received <font color="blue">purchase orders</font> and made a <font color="blue">significant</font> portion of each     quarter’s <font color="blue">product shipments</font> near the end of the quarter</td>
    </tr>
    <tr>
      <td>If that pattern     continues,  even  short delays in the receipt of orders or shipment of     <font color="blue">products at</font> the end of a quarter could have a material <font color="blue">adverse affect on</font>     results of <font color="blue">operations</font> for that quarter</td>
    </tr>
    <tr>
      <td>We expend <font color="blue">significant</font> resources educating and providing information to our     <font color="blue">prospective customers</font> regarding the uses and benefits of our products</td>
    </tr>
    <tr>
      <td>Because of the number of <font color="blue">factors influencing</font> the <font color="blue">sales process</font>, the period     between our <font color="blue">initial contact with</font> a customer and the time when we recognize     revenues  from that customer, if ever, varies widely</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">sales cycle</font>s</font>     <font color="blue">typically range from three</font> to six months, but can be much longer</td>
    </tr>
    <tr>
      <td><font color="blue">During     </font>these  cycles, we commit substantial resources to our <font color="blue">sales efforts</font> in     advance of receiving any revenues, and we may never receive any revenues     from a <font color="blue">customer despite</font> our <font color="blue">sales efforts</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">relatively</font> high purchase price for a customer order <font color="blue">contributes</font> to     <font color="blue">collection delays</font> that result in working <font color="blue">capital <font color="blue">volatility</font></font></td>
    </tr>
    <tr>
      <td>While the terms     of our sales orders <font color="blue">generally</font> require payment within 30 days of product     shipment and do not provide return rights, in the past we have experienced     <font color="blue">significant</font> <font color="blue">collection delays</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot <font color="blue">predict whether</font></font> we <font color="blue">will continue</font> to     experience similar or more <font color="blue">severe delays</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">capital spending policies</font> of our customers have a <font color="blue">significant</font> effect on     the demand for our products</td>
    </tr>
    <tr>
      <td>Those policies are <font color="blue">based on</font> a wide variety of     factors,  including  resources  available  to make purchases, spending     priorities, and policies regarding <font color="blue">capital <font color="blue">expenditures</font> during industry</font>     downturns or <font color="blue">recessionary periods</font></td>
    </tr>
    <tr>
      <td>Any decrease in <font color="blue">capital spending by</font> our     customers resulting from any of these <font color="blue">factors could harm</font> our business</td>
    </tr>
    <tr>
      <td>We <font color="blue"><font color="blue">depend on</font> orders</font> that are received and shipped in the <font color="blue">same quarter</font> and     therefore have limited <font color="blue">visibility</font> of <font color="blue">future <font color="blue">product shipments</font></font></td>
    </tr>
    <tr>
      <td>Our net sales in any <font color="blue">given quarter depend upon</font> a <font color="blue">combination</font> of orders     received in that quarter for shipment in that quarter and <font color="blue">shipments from</font>     backlog</td>
    </tr>
    <tr>
      <td>Our products are <font color="blue">typically shipped within ninety days</font> of purchase     order receipt</td>
    </tr>
    <tr>
      <td>As a result, we do not believe that the amount of backlog at     any particular date is <font color="blue">indicative</font> of our future level of sales</td>
    </tr>
    <tr>
      <td>Our backlog     at the beginning of <font color="blue">each quarter</font> does not include all <font color="blue">product sales</font> needed     to  achieve  expected  revenues for that quarter</td>
    </tr>
    <tr>
      <td>Consequently, we are     <font color="blue">dependent on</font> obtaining orders for products to be shipped in the <font color="blue">same quarter</font>     that the order is received</td>
    </tr>
    <tr>
      <td>Moreover, <font color="blue">customers may reschedule shipments</font>,     and production <font color="blue">difficult</font>ies could delay shipments</td>
    </tr>
    <tr>
      <td>Accordingly, we have     limited  <font color="blue">visibility</font>  of  future  <font color="blue">product shipments</font>, and our results of     <font color="blue">operations</font> are subject to <font color="blue">significant</font> <font color="blue">variability</font> from quarter to quarter</td>
    </tr>
    <tr>
      <td>Many of our current and potential <font color="blue"><font color="blue">competitor</font>s</font> have <font color="blue">significant</font>ly greater     resources than we do, and increased <font color="blue">competition</font> could impair sales of our     products</td>
    </tr>
    <tr>
      <td>We  operate in a <font color="blue">highly <font color="blue">competitive</font> industry</font> and face <font color="blue">competition</font> from     companies that design, <font color="blue">manufacture</font> and <font color="blue">market instruments</font> for use in the     <font color="blue"><font color="blue">life sciences</font> <font color="blue">research industry</font></font>, from genomic, <font color="blue">pharmaceutical</font>, <font color="blue">bio<font color="blue">technology</font></font>     and <font color="blue">diagnostic companies</font> and from academic and <font color="blue">research <font color="blue">institutions</font></font> and     <font color="blue">government</font> or other publicly-funded agencies, both in the <font color="blue"><font color="blue">United States</font> </font>and     elsewhere</td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue">compete <font color="blue">effective</font>ly with</font> all of these     <font color="blue"><font color="blue">competitor</font>s</font></td>
    </tr>
    <tr>
      <td>Many  of  these  companies and <font color="blue">institutions</font> have greater     financial,  <font color="blue">engineering</font>, <font color="blue">manufacturing</font>, marketing and <font color="blue">customer support</font>     resources than we do</td>
    </tr>
    <tr>
      <td>As a result, our <font color="blue"><font color="blue">competitor</font>s</font> may be able to respond     more quickly to new or emerging <font color="blue">technologies</font> or market <font color="blue"><font color="blue">development</font>s</font> by     devoting  greater  resources to the <font color="blue">development</font>, promotion and sale of     products, <font color="blue">which could</font> impair sales of our products</td>
    </tr>
    <tr>
      <td>Moreover, there has been     <font color="blue">significant</font>  merger and <font color="blue"><font color="blue">acquisition</font> activity among</font> our <font color="blue"><font color="blue">competitor</font>s</font> and     potential <font color="blue"><font color="blue">competitor</font>s</font></td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">transactions</font> by</font> our <font color="blue"><font color="blue">competitor</font>s</font> and potential     <font color="blue"><font color="blue">competitor</font>s</font>  may  <font color="blue">provide them with</font> a <font color="blue"><font color="blue">competitive</font> advantage over us by</font>     enabling  them  to  <font color="blue">rapidly expand</font> their <font color="blue">product offerings</font> and service     <font color="blue">capabilities</font>  to  meet  a <font color="blue">broader range</font> of customer needs</td>
    </tr>
    <tr>
      <td>Many of our     customers and <font color="blue">potential customers</font> are large companies that require global     support and service, which may be easier for our larger <font color="blue"><font color="blue">competitor</font>s</font> to     provide</td>
    </tr>
    <tr>
      <td>We believe that <font color="blue">competition</font> within the markets we serve is <font color="blue">primarily driven</font>     by the need for <font color="blue">innovative products</font> that address the needs of customers</td>
    </tr>
    <tr>
      <td>We     attempt  to counter <font color="blue">competition</font> by seeking to develop <font color="blue">new products</font> and     <font color="blue">provide quality products</font> and services that <font color="blue">meet customers</font>’ needs</td>
    </tr>
    <tr>
      <td>We cannot     assure you, however, that                                         12       _________________________________________________________________    [78]Table of <font color="blue">Contents       </font>we will be able to <font color="blue">successfully</font> develop <font color="blue">new products</font> or that our existing or     <font color="blue">new products</font> and <font color="blue">services will adequately meet</font> our customers’ needs</td>
    </tr>
    <tr>
      <td><font color="blue">Rapidly  </font>changing  <font color="blue">technology</font>, evolving industry standards, changes in     customer needs, emerging <font color="blue">competition</font> and <font color="blue">frequent new product</font> and service     <font color="blue">introductions</font>  <font color="blue">characterize</font>  the  markets  for our products</td>
    </tr>
    <tr>
      <td>To remain     <font color="blue">competitive</font>, we will be required to develop <font color="blue">new products</font> and <font color="blue">periodically</font>     enhance our <font color="blue">existing products</font> in a <font color="blue">timely manner</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">facing increased</font>     <font color="blue">competition</font> as new companies entering the market with new <font color="blue">technologies</font>     compete, or will compete, with our products and <font color="blue">future products</font></td>
    </tr>
    <tr>
      <td>We cannot     assure  you  that  one  or more of our <font color="blue"><font color="blue">competitor</font>s</font> will not succeed in     developing or marketing <font color="blue">technologies</font> or products that are more <font color="blue">effective</font> or     <font color="blue"><font color="blue">commercially</font> attractive than</font> our products or <font color="blue">future products</font>, or that would     render our <font color="blue">technologies</font> and <font color="blue">products obsolete</font> or uneconomical</td>
    </tr>
    <tr>
      <td>Our future     <font color="blue">success will depend</font> in large part on our ability to maintain a <font color="blue">competitive</font>     <font color="blue">position with respect</font> to our current and future <font color="blue">technologies</font>, which we may     not be able to do</td>
    </tr>
    <tr>
      <td>In addition, delays in the launch of our <font color="blue">new products</font> may     result  in  loss  of  market  share due to our customers’ purchases of     <font color="blue"><font color="blue">competitor</font>s</font>’ products during any delay</td>
    </tr>
    <tr>
      <td>If we are not successful in developing new and <font color="blue">enhanced products</font>, we may     <font color="blue">lose market</font> share to our <font color="blue"><font color="blue">competitor</font>s</font></td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">life sciences</font> research instrumentation market</font> is <font color="blue">characterize</font>d by rapid     <font color="blue">technological</font> change and <font color="blue">frequent new product</font> <font color="blue">introductions</font></td>
    </tr>
    <tr>
      <td>In the twelve     months ended <font color="blue">December </font>31, 2005, 70prca of our revenues were <font color="blue">derived from</font> the     sale of products that were introduced in the <font color="blue">last three years</font>, and our     future <font color="blue">success will depend</font> on our ability to enhance our <font color="blue">current products</font>     and to develop and introduce, on a <font color="blue">timely basis</font>, <font color="blue">new products</font> that address     the evolving needs of our customers</td>
    </tr>
    <tr>
      <td>We may experience <font color="blue">difficult</font>ies or     delays in our <font color="blue"><font color="blue">development</font> efforts with respect</font> to <font color="blue">new products</font>, and we may     not ultimately be successful in developing or commercializing them, which     would harm our business</td>
    </tr>
    <tr>
      <td>Any <font color="blue">significant</font> delay in <font color="blue">releasing <font color="blue">new systems</font></font>     could cause our revenues to suffer, <font color="blue">adversely</font> affect our reputation, give a     <font color="blue">competitor</font> a first-to-market advantage or cause a <font color="blue">competitor</font> to achieve     greater  market  share</td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">future <font color="blue">success depends on</font></font> our     <font color="blue">continued ability</font> to develop <font color="blue">new <font color="blue">applications</font></font> for our <font color="blue">existing products</font></td>
    </tr>
    <tr>
      <td>If     we are not able to complete the <font color="blue">development</font> of these <font color="blue">applications</font>, or if we     experience <font color="blue">difficult</font>ies or delays, we may lose our <font color="blue">current customers</font> and may     not  be  able to attract new customers, <font color="blue">which could</font> seriously harm our     business and our <font color="blue">future growth prospects</font></td>
    </tr>
    <tr>
      <td>We must expend a <font color="blue">significant</font> amount of time and resources to develop new     products, and if these products do not achieve <font color="blue">commercial <font color="blue">acceptance</font></font>, our     operating results may suffer</td>
    </tr>
    <tr>
      <td>We expect to spend a <font color="blue">significant</font> amount of time and resources to develop new     products  and  refine  <font color="blue">existing products</font></td>
    </tr>
    <tr>
      <td>In light of the <font color="blue">long product</font>     <font color="blue">development</font> cycles inherent in our industry, these <font color="blue"><font color="blue">expenditures</font> will</font> be made     well in advance of the prospect of <font color="blue">deriving <font color="blue">revenues from</font></font> the sale of new     products</td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue"><font color="blue">commercially</font> introduce</font> and <font color="blue">successfully</font> market new     products is subject to a wide variety of <font color="blue">challenges during</font> this <font color="blue">development</font>     cycle that <font color="blue">could delay introduction</font> of these products</td>
    </tr>
    <tr>
      <td>In addition, since     our customers are not obligated by long-term contracts to purchase our     products, our anticipated <font color="blue">product orders may</font> not <font color="blue">materialize</font>, or orders that     do <font color="blue">materialize</font> may be canceled</td>
    </tr>
    <tr>
      <td>As a result, if we do not achieve market     <font color="blue">acceptance</font> of <font color="blue">new products</font>, our operating results will suffer</td>
    </tr>
    <tr>
      <td>Our products     are also <font color="blue">generally</font> priced <font color="blue">higher than</font> <font color="blue">competitive</font> products, which may impair     <font color="blue">commercial <font color="blue">acceptance</font></font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot <font color="blue">predict whether</font></font> <font color="blue">new products</font> that we expect     to <font color="blue">introduce will</font> achieve <font color="blue">commercial <font color="blue">acceptance</font></font></td>
    </tr>
    <tr>
      <td>We obtain some of the <font color="blue">consumables</font>, <font color="blue">components</font> and <font color="blue"><font color="blue">subassemblies</font> used with</font> or     included in our <font color="blue">systems from</font> a <font color="blue">single source</font> or limited group of suppliers,     and the partial or complete loss of one of these <font color="blue">suppliers could</font> cause     <font color="blue">customer supply</font> or <font color="blue">production delays</font> and a substantial loss of revenues</td>
    </tr>
    <tr>
      <td>We  rely  on  outside  vendors to <font color="blue">manufacture</font> some of the <font color="blue">consumables</font>,     <font color="blue">components</font> and <font color="blue"><font color="blue">subassemblies</font> used with</font> or included in our systems</td>
    </tr>
    <tr>
      <td><font color="blue">Certain     </font><font color="blue">consumables</font>,  <font color="blue">components</font>, <font color="blue">subassemblies</font> and <font color="blue">services <font color="blue">necessary</font></font> for the     <font color="blue">manufacture</font> of our systems are obtained from a <font color="blue">sole supplier</font> or limited     group  of  suppliers,  some  of  which are our <font color="blue"><font color="blue">competitor</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>    <font color="blue">components</font>, such as optical, electronic and <font color="blue">pneumatic devices</font>, are currently     purchased in <font color="blue">configurations specific</font> to our <font color="blue">requirements</font> and, <font color="blue">together with</font>     certain  other  <font color="blue">components</font>, such as computers, are <font color="blue">integrated into</font> our     products</td>
    </tr>
    <tr>
      <td>We maintain only a limited number of long-term supply <font color="blue">agreements</font>     with our suppliers,                                         13       _________________________________________________________________    [79]Table of <font color="blue">Contents       </font>and some of these <font color="blue">agreements</font> provide that the supplier is the exclusive     supplier of a <font color="blue">particular consumable</font>, component or <font color="blue">subassembly</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">reliance on</font> a sole or a limited group of suppliers involves several     risks, including the following:         •  our <font color="blue">suppliers may</font> cease or <font color="blue">interrupt production</font> of required     <font color="blue">consumables</font>, <font color="blue">components</font> or <font color="blue">subassemblies</font> or <font color="blue">otherwise fail</font> to <font color="blue">supply us with</font>     an <font color="blue">adequate supply</font> of required <font color="blue">consumables</font>, <font color="blue">components</font> or <font color="blue">subassemblies</font> for     a number of reasons, including <font color="blue">contractual disputes with</font> our suppliers or     adverse financial <font color="blue"><font color="blue">development</font>s</font> at or <font color="blue">affecting</font> the supplier;          •  we have reduced control over the pricing of third party-supplied     <font color="blue">consumables</font>, <font color="blue">components</font> and <font color="blue">subassemblies</font>, and our <font color="blue">suppliers may</font> be unable     or  unwilling  to  <font color="blue">supply us with</font> required <font color="blue">consumables</font>, <font color="blue">components</font> and     <font color="blue">subassemblies</font> on <font color="blue">commercially</font> acceptable terms, or at all;          •   we  have  reduced  control  over  the  <font color="blue">timely delivery</font> of third     party-supplied <font color="blue">consumables</font>, <font color="blue">components</font> and <font color="blue">subassemblies</font>; and          •   our <font color="blue">suppliers may</font> be unable to develop <font color="blue">technological</font>ly advanced     products to support our growth and <font color="blue">development</font> of <font color="blue">new systems</font></td>
    </tr>
    <tr>
      <td>Because the <font color="blue">manufacturing</font> of certain of these <font color="blue">consumables</font>, <font color="blue">components</font> and     <font color="blue">subassemblies</font> involves extremely complex processes and requires long lead     times, we may experience delays or shortages caused by suppliers</td>
    </tr>
    <tr>
      <td>We believe     that <font color="blue"><font color="blue">alternative</font> sources could</font> be obtained and qualified, if <font color="blue">necessary</font>, for     most sole and limited <font color="blue">source parts</font>, subject in <font color="blue">certain cases</font> to the terms of     exclusive supply <font color="blue">agreements</font> with suppliers</td>
    </tr>
    <tr>
      <td>However, if we were forced to     <font color="blue">seek <font color="blue">alternative</font> sources</font> of supply or to <font color="blue">manufacture</font> such <font color="blue">consumables</font>,     <font color="blue">components</font> or <font color="blue">subassemblies</font> internally, we may be forced to redesign our     systems, <font color="blue">which could</font> prevent us from shipping our systems to <font color="blue">customers on</font> a     <font color="blue">timely basis</font>, and we may be liable to <font color="blue">suppliers under</font> the terms of existing     supply <font color="blue">agreements</font></td>
    </tr>
    <tr>
      <td>Some of our suppliers have <font color="blue">relatively</font> limited financial     and other resources</td>
    </tr>
    <tr>
      <td>Any <font color="blue">inability</font> to obtain <font color="blue">adequate deliveries</font>, or any     other circumstance that <font color="blue">would restrict</font> our ability to ship our products,     could damage <font color="blue"><font color="blue">relationships</font> with</font> current and <font color="blue">prospective customers</font> and could     harm our business, and any disputes with <font color="blue">suppliers could</font> have an adverse     <font color="blue">impact on</font> our business, <font color="blue">financial condition</font> or results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We may encounter <font color="blue">manufacturing</font> and <font color="blue">assembly problems</font> or delays, <font color="blue">which could</font>     result in <font color="blue">lost revenues</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">manufacture</font> our <font color="blue">products at</font> our <font color="blue">facilities</font> in Sunnyvale and Union City,     both in California, and in Norway</td>
    </tr>
    <tr>
      <td>We assemble the Discovery-1 system at our     <font color="blue">facility</font>  in Downingtown, Pennsylvania</td>
    </tr>
    <tr>
      <td>Our <font color="blue">manufacturing</font> and assembly     processes are <font color="blue">highly complex</font> and require sophisticated, costly equipment and     specially designed <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>As a result, any prolonged <font color="blue">disruption</font> in the     <font color="blue">operations</font> of our <font color="blue">manufacturing</font> <font color="blue">facilities</font> could seriously harm our ability     to satisfy our customer order <font color="blue">deadlines</font></td>
    </tr>
    <tr>
      <td>If we cannot deliver our systems in     a <font color="blue">timely manner</font>, our <font color="blue">revenues will likely suffer</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">product sales</font> depend in part upon <font color="blue">manufacturing</font> yields</td>
    </tr>
    <tr>
      <td>We currently     have  limited  <font color="blue">manufacturing</font>  <font color="blue">capacity</font>  and  experience <font color="blue">variability</font> in     <font color="blue">manufacturing</font>  yields</td>
    </tr>
    <tr>
      <td>We are currently <font color="blue">manufacturing</font> high-throughput     instruments in-house, in limited volumes and <font color="blue">with largely manual assembly</font></td>
    </tr>
    <tr>
      <td>If demand for our high-throughput instruments increases, we will either need     to expand our in-house <font color="blue">manufacturing</font> <font color="blue">capabilities</font> or outsource to other     <font color="blue">manufacture</font>rs</td>
    </tr>
    <tr>
      <td>If we fail to deliver our products in a <font color="blue">timely manner</font>, our     <font color="blue"><font color="blue">relationships</font> with</font> our <font color="blue">customers could</font> be <font color="blue">seriously harmed</font>, and our revenues     <font color="blue">could decline</font></td>
    </tr>
    <tr>
      <td>As we develop <font color="blue">new products</font>, we <font color="blue">must transition</font> the <font color="blue">manufacture</font> of a new     <font color="blue">product from</font> the <font color="blue">development</font> stage to commercial <font color="blue">manufacturing</font></td>
    </tr>
    <tr>
      <td>We cannot     <font color="blue">predict whether</font> we will be able to complete these <font color="blue">transitions on</font> a timely     basis and <font color="blue">with <font color="blue">commercially</font> <font color="blue">reasonable costs</font></font></td>
    </tr>
    <tr>
      <td>We cannot assure you that     <font color="blue">manufacturing</font> or <font color="blue">quality control</font> problems will not arise as we attempt to     scale-up our production for any future <font color="blue">new products</font> or that we can scale-up     <font color="blue">manufacturing</font> and <font color="blue">quality control</font> in a <font color="blue">timely manner</font> or <font color="blue">at <font color="blue">commercially</font></font>     <font color="blue">reasonable costs</font></td>
    </tr>
    <tr>
      <td>If we are unable to consistently <font color="blue">manufacture</font> our products     on a <font color="blue">timely basis</font> because of these or other factors, our <font color="blue">product sales</font> will     decline</td>
    </tr>
    <tr>
      <td>14       _________________________________________________________________    [80]Table of <font color="blue">Contents       </font>If we deliver <font color="blue">products with defects</font>, our <font color="blue"><font color="blue">credibility</font> will</font> be harmed and the     sales and market <font color="blue">acceptance</font> of our <font color="blue">products will decrease</font></td>
    </tr>
    <tr>
      <td>Our products are complex and have at times contained errors, defects and     bugs when introduced</td>
    </tr>
    <tr>
      <td>If we deliver products with errors, defects or bugs,     our <font color="blue">credibility</font> and the market <font color="blue">acceptance</font> and sales of our <font color="blue">products would</font> be     harmed</td>
    </tr>
    <tr>
      <td>Further, if our products contain errors, defects or bugs, we may be     required to expend <font color="blue">significant</font> capital and resources to <font color="blue">alleviate such</font>     problems</td>
    </tr>
    <tr>
      <td>Defects <font color="blue">could also lead</font> to <font color="blue">product <font color="blue">liability</font> as</font> a result of     <font color="blue">product <font color="blue">liability</font> lawsuits <font color="blue">against us</font></font> or against our customers</td>
    </tr>
    <tr>
      <td>We have     agreed to indemnify our customers in some <font color="blue">circumstances against <font color="blue">liability</font></font>     arising <font color="blue">from defects</font> in our products</td>
    </tr>
    <tr>
      <td>In the event of a <font color="blue">successful product</font>     <font color="blue">liability</font> claim, we could be obligated to pay damages <font color="blue">significant</font>ly in     excess of our product <font color="blue">liability</font> insurance limits</td>
    </tr>
    <tr>
      <td>We have <font color="blue">significant</font>ly expanded our <font color="blue">international</font> <font color="blue">operations</font>, which exposes     us to <font color="blue">risks inherent</font> in <font color="blue">international</font> business <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>We maintain <font color="blue">facilities</font> in the United Kingdom, Germany, Norway, Japan, South     Korea, Australia and China</td>
    </tr>
    <tr>
      <td>In addition to the increase in our <font color="blue">international</font>     <font color="blue">operations</font>, we are <font color="blue">also deriving</font> an increasing portion of our <font color="blue">revenues from</font>     <font color="blue">customers located outside</font> of the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Sales to customers outside     of the <font color="blue"><font color="blue">United States</font> </font>accounted for approximately 44prca our revenues during the     year ended <font color="blue">December </font>31, 2005 and we anticipate that <font color="blue">international</font> sales will     continue to account for a <font color="blue">significant</font> portion of our revenues</td>
    </tr>
    <tr>
      <td>A key aspect     of our business strategy has been and is to expand our sales and support     organizations <font color="blue">international</font>ly in order to take advantage of increasing     <font color="blue">international</font> market opportunities resulting <font color="blue">from worldwide growth</font> in the     <font color="blue"><font color="blue">life sciences</font> <font color="blue">research industry</font></font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">reliance on</font> <font color="blue">international</font> sales and <font color="blue">operations</font> exposes us to a number of     risks associated with conducting <font color="blue">operations</font> <font color="blue">international</font>ly, including:         •  political, social and <font color="blue">economic instability</font>;         •  <font color="blue">trade <font color="blue">restrictions</font></font> and changes in tariffs;         •  the impact of business cycles and downturns in <font color="blue">economies outside</font> of the     <font color="blue">United States</font>;          •  unexpected changes in regulatory <font color="blue">requirements</font> that may limit our     ability to export our products or <font color="blue">sell into particular <font color="blue">jurisdictions</font></font>;         •  import and export license <font color="blue">requirements</font> and <font color="blue">restrictions</font>;          •   <font color="blue">difficult</font>ies  and  costs  of  staffing, managing and monitoring     geographically disparate <font color="blue">operations</font>;         •  <font color="blue">difficult</font>ies in maintaining <font color="blue">effective</font> communications with employees and     <font color="blue">customers due</font> to distance, language and <font color="blue">cultural barriers</font>;         •  <font color="blue">disruption</font>s in <font color="blue">international</font> transport or delivery;          •   <font color="blue">difficult</font>ies  in  protecting  our <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font>,     <font color="blue">particularly</font>  in countries where the laws and practices do not protect     <font color="blue"><font color="blue">proprietary</font> rights</font> to as great an extent as do the laws and practices of the     <font color="blue">United States</font>;         •  <font color="blue">difficult</font>ies in enforcing <font color="blue">agreements</font> through non-US legal systems;         •  <font color="blue">longer payment cycles</font> and <font color="blue">difficult</font>ies in <font color="blue">collecting receivables</font>; and         •  <font color="blue">potentially adverse tax consequences</font></td>
    </tr>
    <tr>
      <td>If any of these risks <font color="blue">materialize</font>, our <font color="blue">international</font> sales could decrease     and our foreign <font color="blue">operations</font> could suffer</td>
    </tr>
    <tr>
      <td>In addition, all of our sales to <font color="blue">international</font> <font color="blue">distributors</font> are <font color="blue">denominated</font>     in US dollars</td>
    </tr>
    <tr>
      <td>Most of our direct sales in the United Kingdom, Germany,     France, the Benelux, Scandinavia, Canada, Japan, South Korea and China are     <font color="blue">denominated</font> in <font color="blue">local currencies</font> and totaled dlra53dtta4 million (29prca of total     revenues) for the year ended <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>To the extent that our sales     and operating expenses are <font color="blue">denominated</font> in foreign currencies, our operating     results may be <font color="blue">adversely</font> affected by changes in <font color="blue">exchange rates</font></td>
    </tr>
    <tr>
      <td>Owing to the     number  of <font color="blue">currencies involved</font>, the substantial <font color="blue">volatility</font> of currency     <font color="blue">exchange rates</font>, and our <font color="blue">constantly</font> changing <font color="blue">currency exposures</font>, we cannot                                         15       _________________________________________________________________    [81]Table of <font color="blue">Contents       </font>predict the effect of exchange rate <font color="blue">fluctuations</font> on our future operating     results</td>
    </tr>
    <tr>
      <td>We  do  not  currently  engage  in  <font color="blue">foreign currency hedging</font>     <font color="blue">transactions</font>, but may do so in the future</td>
    </tr>
    <tr>
      <td>Most of our current and <font color="blue">potential customers</font> are from the <font color="blue">pharmaceutical</font> and     <font color="blue">bio<font color="blue">technology</font></font> <font color="blue">industries</font> and are subject to risks faced by those <font color="blue">industries</font></td>
    </tr>
    <tr>
      <td>We derive a <font color="blue">significant</font> portion of our <font color="blue">revenues from</font> sales to <font color="blue">pharmaceutical</font>     and <font color="blue">bio<font color="blue">technology</font></font> companies</td>
    </tr>
    <tr>
      <td>We expect that sales to <font color="blue">pharmaceutical</font> and     <font color="blue">bio<font color="blue">technology</font></font> companies <font color="blue">will continue</font> to be a <font color="blue">primary source</font> of revenues for     the  foreseeable  future</td>
    </tr>
    <tr>
      <td>As  a  result,  we are subject to risks and     <font color="blue">uncertainties</font> that affect the <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font> <font color="blue">industries</font>,     such as <font color="blue">availability</font> of capital and reduction and delays in research and     <font color="blue">development</font> <font color="blue">expenditures</font> by companies in these <font color="blue">industries</font>, pricing pressures     as third-party payers continue <font color="blue">challenging</font> the pricing of medical products     and services, <font color="blue">government</font> regulation, and the <font color="blue">uncertainty</font> resulting from     <font color="blue">technological</font> change</td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">future revenues may</font> be <font color="blue">adversely</font> affected by the ongoing     <font color="blue">consolidation</font> in the <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font> <font color="blue">industries</font>, which     would reduce the number of our <font color="blue">potential customers</font></td>
    </tr>
    <tr>
      <td>Furthermore, we cannot     assure you that the <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font> companies that are our     customers  will  not  develop their own <font color="blue">competing products</font> or in-house     <font color="blue">capabilities</font></td>
    </tr>
    <tr>
      <td>Our products could infringe on the <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font> of others,     which  may  cause us to engage in <font color="blue">costly <font color="blue">litigation</font></font> and, if we are not     successful, could also cause us to pay substantial damages and <font color="blue">prohibit us</font>     <font color="blue">from selling</font> our products</td>
    </tr>
    <tr>
      <td>Third <font color="blue">parties may</font> assert <font color="blue">infringement</font> or other <font color="blue"><font color="blue">intellectual</font> property</font> claims     <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td>We may have to pay substantial damages for <font color="blue">infringement</font> if it is     ultimately  determined  that  our <font color="blue">products infringe on</font> a third party’s     <font color="blue"><font color="blue">proprietary</font> rights</font></td>
    </tr>
    <tr>
      <td>Further, any legal action <font color="blue">against us</font> could, in addition     to  subjecting us to potential <font color="blue">liability</font> for damages, <font color="blue">prohibit us</font> from     selling our products before we obtain a license to do so from the party     owning the <font color="blue"><font color="blue">intellectual</font> property</font>, which, if available at all, may require us     to  pay substantial royalties</td>
    </tr>
    <tr>
      <td>Even if these claims are <font color="blue">without merit</font>,     defending a lawsuit takes <font color="blue">significant</font> time, may be expensive and may divert     <font color="blue"><font color="blue">management</font> <font color="blue">attention from</font></font> other business concerns</td>
    </tr>
    <tr>
      <td>There may be third-party     patents that may relate to our <font color="blue">technology</font> or <font color="blue">potential products</font></td>
    </tr>
    <tr>
      <td>Any public     <font color="blue">announcements</font> related to <font color="blue">litigation</font> or <font color="blue"><font color="blue">interference proceedings</font> initiated</font> or     threatened <font color="blue">against us</font> could cause our stock price to decline</td>
    </tr>
    <tr>
      <td>We believe     that there may be <font color="blue">significant</font> <font color="blue">litigation</font> in the industry regarding patent     and other <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">become involved</font> in <font color="blue">litigation</font>,     it <font color="blue">could consume</font> a substantial portion of our managerial and financial     resources</td>
    </tr>
    <tr>
      <td>We may need to initiate lawsuits to protect or enforce our patents, which     would  be  expensive and, if we lose, may cause us to lose some of our     <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font>, which would reduce our ability to compete in     the market</td>
    </tr>
    <tr>
      <td>We <font color="blue">rely on patents</font> to protect a large part of our <font color="blue"><font color="blue">intellectual</font> property</font> and     our <font color="blue">competitive</font> position</td>
    </tr>
    <tr>
      <td>In order to protect or enforce our patent rights,     we  may  initiate  patent  <font color="blue">litigation</font>  against  third parties, such as     <font color="blue">infringement</font> suits or <font color="blue">interference proceedings</font></td>
    </tr>
    <tr>
      <td><font color="blue">Litigation </font>may be <font color="blue">necessary</font>     to:         •  assert claims of <font color="blue">infringement</font>;         •  enforce our patents;         •  protect our <font color="blue">trade secrets</font> or know-how; or         •  determine the enforceability, scope and validity of the <font color="blue">proprietary</font>     rights of others</td>
    </tr>
    <tr>
      <td>Lawsuits could be expensive, take <font color="blue">significant</font> time and divert <font color="blue">management</font>’s     <font color="blue">attention from</font> other business concerns</td>
    </tr>
    <tr>
      <td>They would put our <font color="blue">patents at risk</font>     of being invalidated or <font color="blue">interpreted narrowly</font> and our patent <font color="blue">applications</font> at     risk of not issuing</td>
    </tr>
    <tr>
      <td>We <font color="blue">may also provoke third parties</font> to assert claims     <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td>Patent law relating to the scope of claims in the <font color="blue">technology</font>     fields in which we operate is <font color="blue">still evolving</font> and, consequently, patent     positions in our industry are <font color="blue">generally</font> uncertain</td>
    </tr>
    <tr>
      <td>If initiated, we cannot     assure you that we would prevail in any of these suits or that the damages     or other <font color="blue">remedies awarded</font>, if any, would be <font color="blue">commercially</font> valuable</td>
    </tr>
    <tr>
      <td><font color="blue">During     </font>the course of these suits,                                         16       _________________________________________________________________    [82]Table of <font color="blue">Contents       </font><font color="blue">there could</font> be public <font color="blue">announcements</font> of the results of hearings, motions and     other <font color="blue">interim proceedings</font> or <font color="blue"><font color="blue">development</font>s</font> in the <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>If securities     analysts or investors were to perceive any of these results to be negative,     our stock price <font color="blue">could decline</font></td>
    </tr>
    <tr>
      <td>The rights we rely upon to protect our <font color="blue"><font color="blue">intellectual</font> property</font> underlying our     <font color="blue">products may</font> not be adequate, <font color="blue">which could</font> enable third parties to use our     <font color="blue">technology</font> and would reduce our ability to compete in the market</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">success will depend</font> in part on our ability to obtain <font color="blue">commercially</font>     valuable patent claims and to protect our <font color="blue"><font color="blue">intellectual</font> property</font></td>
    </tr>
    <tr>
      <td>Our patent     position is <font color="blue">generally</font> uncertain and <font color="blue">involves complex legal</font> and factual     questions</td>
    </tr>
    <tr>
      <td>Legal standards relating to the validity and scope of claims in     our <font color="blue">technology</font> field are <font color="blue">still evolving</font></td>
    </tr>
    <tr>
      <td>Therefore, the degree of future     protection for our <font color="blue"><font color="blue">proprietary</font> rights</font> is uncertain</td>
    </tr>
    <tr>
      <td>The risks and <font color="blue">uncertainties</font> that we <font color="blue">face with respect</font> to our patents and     other <font color="blue"><font color="blue">proprietary</font> rights</font> include the following:         •  the pending patent <font color="blue">applications</font> we have filed or to which we have     <font color="blue">exclusive rights may</font> not result in issued patents or may take <font color="blue">longer than</font> we     expect to result in issued patents;         •  the claims of any <font color="blue">patents which</font> are <font color="blue">issued may</font> not provide meaningful     protection;         •  we may not be able to develop additional <font color="blue">proprietary</font> <font color="blue">technologies</font> that     are patentable;         •  the <font color="blue">patents licensed</font> or issued to us or our customers may not provide a     <font color="blue">competitive</font> advantage;         •  other companies may challenge <font color="blue">patents licensed</font> or issued to us or our     customers;         •  <font color="blue">patents issued</font> to other <font color="blue">companies may harm</font> our ability to do business;          •  other <font color="blue">companies may <font color="blue">independently</font></font> develop similar or <font color="blue">alternative</font>     <font color="blue">technologies</font> or duplicate our <font color="blue">technologies</font>; and         •  other <font color="blue">companies may design around</font> the <font color="blue">technologies</font> we have licensed or     developed</td>
    </tr>
    <tr>
      <td>In  addition  to  patents,  we rely on a <font color="blue">combination</font> of <font color="blue">trade secrets</font>,     nondisclosure <font color="blue">agreements</font> and other <font color="blue">contractual provisions</font> and technical     measures to protect our <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font></td>
    </tr>
    <tr>
      <td>Nevertheless, these     measures  may  not be adequate to safeguard the <font color="blue">proprietary</font> <font color="blue">technology</font>     underlying our products</td>
    </tr>
    <tr>
      <td>If these measures do not protect our rights, third     <font color="blue">parties could use</font> our <font color="blue">technology</font>, and our ability to compete in the market     would  be  reduced</td>
    </tr>
    <tr>
      <td>In addition, employees, consultants and others who     <font color="blue">participate</font> in the <font color="blue">development</font> of our <font color="blue">products may</font> breach their <font color="blue">agreements</font>     with us regarding our <font color="blue"><font color="blue">intellectual</font> property</font>, and we may not have adequate     remedies for the breach</td>
    </tr>
    <tr>
      <td>We also may not be able to <font color="blue">effective</font>ly protect our     <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font> in some <font color="blue">foreign countries</font></td>
    </tr>
    <tr>
      <td>For a variety of     reasons,  we may decide not to file for patent, copyright or trademark     protection or prosecute potential <font color="blue">infringement</font>s of our patents</td>
    </tr>
    <tr>
      <td>We also     realize that our <font color="blue">trade secrets</font> may become known through other means not     currently  foreseen  by us</td>
    </tr>
    <tr>
      <td><font color="blue">Notwithstanding </font>our efforts to protect our     <font color="blue"><font color="blue">intellectual</font> property</font>, our <font color="blue"><font color="blue">competitor</font>s</font> may design around our <font color="blue">proprietary</font>     <font color="blue">technologies</font>  or  may  <font color="blue">independently</font>  develop  similar  or <font color="blue">alternative</font>     <font color="blue">technologies</font> or products that are equal or superior to our <font color="blue">technology</font> and     <font color="blue">products without infringing on</font> any of our <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font></td>
    </tr>
    <tr>
      <td>We may have <font color="blue">difficult</font>y managing our growth</td>
    </tr>
    <tr>
      <td>We expect to experience <font color="blue">significant</font> growth in the number of our employees     and customers and the scope of our <font color="blue">operations</font>, including as a result of     <font color="blue">potential <font color="blue"><font color="blue">acquisition</font>s</font></font></td>
    </tr>
    <tr>
      <td>This <font color="blue">growth may continue</font> to place a <font color="blue">significant</font>     strain on our <font color="blue">management</font> and <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our ability to manage this growth     <font color="blue">will depend upon</font> our ability to broaden our <font color="blue">management</font> team and our ability     to attract, hire and retain <font color="blue">skilled employees</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will also depend</font>     on the ability of our officers and <font color="blue">key employees</font> to continue to implement     and  improve  our  operational  and other systems, to manage multiple,     <font color="blue">concurrent</font>  customer  <font color="blue">relationships</font>  and to hire, train and manage our     employees</td>
    </tr>
    <tr>
      <td>Our  future  success  is <font color="blue">heavily dependent upon growth</font> and     <font color="blue">acceptance</font> of <font color="blue">new products</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">cannot scale</font> our business <font color="blue"><font color="blue">appropriate</font>ly</font> or     <font color="blue">otherwise adapt</font> to anticipated growth and new product <font color="blue">introductions</font>, a key     part of our <font color="blue">strategy may</font> not be successful</td>
    </tr>
    <tr>
      <td>17       _________________________________________________________________    [83]Table of <font color="blue">Contents       </font>We <font color="blue">rely upon <font color="blue">distributors</font></font> for <font color="blue">product sales</font> and <font color="blue">support outside</font> of North     America</td>
    </tr>
    <tr>
      <td>In the year ended <font color="blue">December </font>31, 2005, approximately 11prca of our sales were     made  <font color="blue">through <font color="blue">distributors</font></font></td>
    </tr>
    <tr>
      <td>We often <font color="blue">rely upon <font color="blue">distributors</font></font> to provide     <font color="blue">customer support</font> to the ultimate end users of our products</td>
    </tr>
    <tr>
      <td>As a result, our     <font color="blue">success depends on</font> the continued sales and <font color="blue">customer support</font> efforts of our     network of <font color="blue">distributors</font></td>
    </tr>
    <tr>
      <td>The use of <font color="blue">distributors</font> involves certain risks,     including risks that <font color="blue">distributors</font> will not <font color="blue">effective</font>ly sell or support our     products, that they will be unable to <font color="blue">satisfy financial obligations</font> to us     and that they will cease <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Any reduction, delay or loss of orders     from our <font color="blue">significant</font> <font color="blue">distributors</font> could harm our revenues</td>
    </tr>
    <tr>
      <td>We also do not     currently have <font color="blue">distributors</font> under contract in a number of <font color="blue">international</font>     markets and may need to establish additional <font color="blue">international</font> distribution     <font color="blue">relationships</font></td>
    </tr>
    <tr>
      <td>There can be no assurance that we will engage qualified     <font color="blue">distributors</font> in a <font color="blue">timely manner</font>, and the failure to do so could have a     material <font color="blue">adverse affect on</font> our business, <font color="blue">financial condition</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If  we choose to acquire new and complementary <font color="blue">businesses</font>, products or     <font color="blue">technologies</font> instead of developing <font color="blue">them ourselves</font>, we may be unable to     complete these <font color="blue"><font color="blue">acquisition</font>s</font> or may not be able to <font color="blue">successfully</font> integrate an     acquired business or <font color="blue">technology</font> in a cost-<font color="blue">effective</font> and non-disruptive     manner</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends on</font> our ability to <font color="blue">continually enhance</font> and broaden our     <font color="blue">product offerings</font> in response to changing <font color="blue">technologies</font>, customer demands and     <font color="blue">competitive</font> pressures</td>
    </tr>
    <tr>
      <td>To this end, from time to time we have acquired     complementary <font color="blue">businesses</font>, products or <font color="blue">technologies</font> instead of developing     <font color="blue">them ourselves</font>, and we may choose to do so in the future</td>
    </tr>
    <tr>
      <td>For example, we     acquired <font color="blue"><font color="blue">intellectual</font> property</font> relating to the Transfluor^® <font color="blue">technology</font> from     Xsira  Pharmaceuticals, Inc</td>
    </tr>
    <tr>
      <td>(“Axon”) in July 2004</td>
    </tr>
    <tr>
      <td>We do not know if we will be able     to complete any additional <font color="blue"><font color="blue">acquisition</font>s</font>, or whether we will be able to     <font color="blue">successfully</font> integrate any acquired business, operate it profitably or     retain its <font color="blue">key employees</font></td>
    </tr>
    <tr>
      <td><font color="blue">Integrating </font>any business, product or <font color="blue">technology</font> we     acquire involves considerable operational and financial risks and strains,     including:         •  the potential <font color="blue">disruption</font> of our ongoing business and <font color="blue">distraction</font> of our     <font color="blue">management</font>;         •  the potential strain on our financial and managerial controls and     reporting systems and procedures;         •  <font color="blue">unanticipated</font> expenses and potential delays related to <font color="blue">integration</font> of     the <font color="blue">operations</font>, <font color="blue">technology</font> and other resources of acquired <font color="blue">businesses</font>;         •  the <font color="blue">impairment</font> of <font color="blue"><font color="blue">relationships</font> with</font> employees, suppliers and customers     as a result of any <font color="blue">integration</font> of new <font color="blue">management</font> personnel;         •  <font color="blue">greater than</font> anticipated costs and expenses related to <font color="blue">restructuring</font>,     including  <font color="blue">employee severance</font> or <font color="blue">relocation costs</font> and costs related to     vacating leased <font color="blue">facilities</font>; and          •   potential  <font color="blue">unknown liabilities associated with</font> any <font color="blue">acquisition</font>,     including  <font color="blue">higher than</font> expected <font color="blue">integration</font> costs, which may cause our     quarterly and annual operating results to fluctuate</td>
    </tr>
    <tr>
      <td>We  may  not  succeed  in <font color="blue">addressing</font> these risks or any other problems     <font color="blue">encountered</font> in <font color="blue">connection with</font> the <font color="blue">acquisition</font> of complementary <font color="blue">businesses</font>,     products or <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">successfully</font> integrate the     <font color="blue">operations</font>, products, <font color="blue">technology</font> and personnel of acquired <font color="blue">businesses</font> in a     <font color="blue">timely manner</font> or at all, or if we do not achieve the perceived benefits of     any <font color="blue">acquisition</font> as rapidly as, or to the extent anticipated by, financial     analysts or investors, the <font color="blue">market price</font> of our <font color="blue"><font color="blue">common stock</font> <font color="blue">could decline</font></font></td>
    </tr>
    <tr>
      <td>In addition, in order to finance any <font color="blue"><font color="blue">acquisition</font>s</font>, we might need to raise     <font color="blue">additional funds through public</font> or <font color="blue">private equity</font> or <font color="blue">debt financings</font></td>
    </tr>
    <tr>
      <td>In     that event, we could be forced to obtain <font color="blue">financing on terms</font> that are not     favorable to us and, in the case of <font color="blue">equity financing</font>, that may result in     dilution to our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>In addition, any <font color="blue">impairment</font> of goodwill and     <font color="blue">amortization</font> of other <font color="blue">intangible assets</font> or charges resulting from the costs     of <font color="blue"><font color="blue">acquisition</font>s</font> could harm our business and operating results</td>
    </tr>
    <tr>
      <td>18       _________________________________________________________________    [84]Table of <font color="blue">Contents       </font>We <font color="blue">depend on</font> our <font color="blue">key personnel</font>, the loss of <font color="blue">whom would impair</font> our ability to     compete</td>
    </tr>
    <tr>
      <td>We  are  highly  <font color="blue">dependent on</font> the <font color="blue">principal members</font> of our <font color="blue">management</font>,     <font color="blue">engineering</font> and <font color="blue">scientific staff</font></td>
    </tr>
    <tr>
      <td>The loss of the service of any of these     <font color="blue">persons could seriously harm</font> our product <font color="blue">development</font> and <font color="blue">commercialization</font>     efforts</td>
    </tr>
    <tr>
      <td>In addition, research, product <font color="blue">development</font> and <font color="blue">commercialization</font>     will require <font color="blue">additional skilled personnel</font> in <font color="blue">areas such as chemistry</font> and     biology, and software and electronic <font color="blue">engineering</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">corporate headquarters</font>     are located in Sunnyvale, California, where demand for <font color="blue">personnel with</font> these     skills  is  extremely  high and is likely to <font color="blue">remain high</font></td>
    </tr>
    <tr>
      <td>As a result,     <font color="blue">competition</font> for and retention of personnel, <font color="blue">particularly</font> for <font color="blue">employees with</font>     technical  expertise,  is  intense and the <font color="blue">turnover rate</font> for qualified     personnel is high</td>
    </tr>
    <tr>
      <td>If we are unable to hire, train and retain a sufficient     number  of  <font color="blue">qualified employees</font>, our ability to conduct and expand our     business  could be <font color="blue">seriously reduced</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">inability</font> to retain and hire     <font color="blue">qualified personnel could also hinder</font> the planned expansion of our business</td>
    </tr>
    <tr>
      <td><font color="blue">Changes  </font>to  financial  <font color="blue">accounting</font> standards may affect our results of     <font color="blue">operations</font> and cause us to change our business practices</td>
    </tr>
    <tr>
      <td>We prepare our <font color="blue">financial statements</font> to <font color="blue">conform with</font> US <font color="blue">generally</font> accepted     <font color="blue">accounting</font>  principles</td>
    </tr>
    <tr>
      <td>These  <font color="blue">accounting</font>  principles  are subject to     interpretation by the American Institute of Certified Public Accountants,     the Public Company Accounting Oversight Board, the SEC and various other     bodies formed to interpret and create <font color="blue">appropriate</font> <font color="blue">accounting</font> principles</td>
    </tr>
    <tr>
      <td>A     change in those principles can have a <font color="blue">significant</font> effect on our reported     results and may affect our reporting of <font color="blue">transactions</font> completed before a     change is announced</td>
    </tr>
    <tr>
      <td>Changes to those rules or the questioning of current     practices may <font color="blue">adversely</font> affect our reported financial results or the way we     conduct our business</td>
    </tr>
    <tr>
      <td>For example, <font color="blue">accounting</font> principles <font color="blue">affecting</font> many     aspects  of  our  business, including rules relating to equity-related     <font color="blue">compensation</font>, have <font color="blue">recently been revised</font> or are <font color="blue">under review</font></td>
    </tr>
    <tr>
      <td>The Financial     Accounting Standards Board and other agencies have finalized changes to     US <font color="blue">generally</font> accepted <font color="blue">accounting</font> principles that require us, starting in     fiscal year 2006, to record a charge to earnings for <font color="blue">employee stock option</font>     grants and other <font color="blue"><font color="blue">equity incentive</font>s</font></td>
    </tr>
    <tr>
      <td>We will have <font color="blue">significant</font> and ongoing     <font color="blue">accounting</font> charges resulting <font color="blue">from option grant</font> and other <font color="blue">equity incentive</font>     expensing that <font color="blue">could reduce</font> our <font color="blue">overall net income</font></td>
    </tr>
    <tr>
      <td>In addition, since we     <font color="blue">historically</font> have used equity-related <font color="blue">compensation</font> as a component of our     total employee <font color="blue">compensation</font> program, the <font color="blue">accounting</font> change could make the     use of equity-related <font color="blue">compensation</font> less attractive to us and therefore make     it more <font color="blue">difficult</font> to attract and retain employees</td>
    </tr>
    <tr>
      <td>See Note 1 of the Notes     to Consolidated Financial Statements for a discussion of the <font color="blue">impact on</font> our     financial results if we were to use the <font color="blue">fair value method</font> of <font color="blue">accounting</font> for     <font color="blue">equity awards</font> to our employees</td>
    </tr>
    <tr>
      <td>Changes in our <font color="blue">effective</font> income tax rate <font color="blue">could reduce</font> our earnings</td>
    </tr>
    <tr>
      <td>Various <font color="blue">factors may</font> have favorable or <font color="blue">unfavorable effects on</font> our <font color="blue">effective</font>     income  tax  rate</td>
    </tr>
    <tr>
      <td>These  factors  include,  but  are not limited to,     <font color="blue">interpretations</font>  of  existing  tax laws, our adoption of the Financial     Accounting Standards Board’s Statement Nodtta 123 (revised 2004), “Share-Based     Payment” relating to the <font color="blue">accounting</font> for <font color="blue">stock options</font> and other share-based     payments, changes in tax laws and rates, future levels of research and     <font color="blue">development</font> spending, changes in <font color="blue">accounting</font> standards, future levels of     capital <font color="blue">expenditures</font>, changes in the mix of earnings in the <font color="blue">various tax</font>     <font color="blue">jurisdictions</font> in which we operate and changes in <font color="blue">overall levels</font> of pre-tax     earnings</td>
    </tr>
    <tr>
      <td>The  impact  on our <font color="blue">income tax provision</font> resulting from the     above-mentioned <font color="blue">factors may</font> be <font color="blue">significant</font> and could have a <font color="blue">negative impact</font>     on our results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our  operating  results  fluctuate  and  any failure to <font color="blue">meet financial</font>     <font color="blue"><font color="blue">expectations</font> may disappoint <font color="blue">securities analysts</font></font> or investors and result in a     decline in our stock price</td>
    </tr>
    <tr>
      <td>We have experienced and in the <font color="blue">future may</font> experience a shortfall in revenues     or earnings or <font color="blue">otherwise fail</font> to meet public market <font color="blue">expectations</font>, which     <font color="blue">could <font color="blue">materially</font></font> and <font color="blue">adversely</font> affect our business and the <font color="blue">market price</font> of     our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">total revenues</font> and operating results <font color="blue">may fluctuate</font>     <font color="blue">significant</font>ly because of a number of factors, many of which are outside of     our control</td>
    </tr>
    <tr>
      <td>These factors include:         •  <font color="blue">customer confidence</font> in the economy, evidenced, in part, <font color="blue">by <font color="blue">stock market</font></font>     levels;          •  changes in the domestic and <font color="blue">international</font> economic, business and     <font color="blue">political conditions</font>;                                         19       _________________________________________________________________    [85]Table of <font color="blue">Contents       </font>    •  <font color="blue">economic conditions within</font> the <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font>     <font color="blue">industries</font>;         •  levels of product and price <font color="blue">competition</font>;         •  the length of our <font color="blue">sales cycle</font> and <font color="blue">customer buying patterns</font>;         •  the size and timing of individual <font color="blue">transactions</font>;         •  the timing of new product <font color="blue">introductions</font> and <font color="blue">product enhancements</font>;         •  the mix of <font color="blue">products sold</font>;         •  levels of <font color="blue">international</font> <font color="blue">transactions</font>;         •  <font color="blue">activities</font> of and <font color="blue"><font color="blue">acquisition</font>s</font> by <font color="blue"><font color="blue">competitor</font>s</font>;         •  the timing of new hires and the <font color="blue">allocation</font> of our resources;         •  changes in foreign currency <font color="blue">exchange rates</font>;         •  our ability to develop and market <font color="blue">new products</font> and <font color="blue">control costs</font>; and         •  changes in US <font color="blue">generally</font> accepted <font color="blue">accounting</font> principles</td>
    </tr>
    <tr>
      <td>One or more of the foregoing <font color="blue">factors may</font> cause our operating expenses to be     <font color="blue">disproportionately high during</font> any <font color="blue">given period</font> or may cause our revenues     and  operating  results  to fluctuate <font color="blue">significant</font>ly</td>
    </tr>
    <tr>
      <td>In particular, we     typically experience a decrease in the level of sales in the <font color="blue">first calendar</font>     <font color="blue">quarter as compared</font> to the <font color="blue">fourth quarter</font> of the <font color="blue">preceding year</font> because of     <font color="blue">budgetary</font> and <font color="blue">capital equipment purchasing patterns</font> in the <font color="blue">life sciences</font>     <font color="blue">research industry</font></td>
    </tr>
    <tr>
      <td>Our quarterly operating results have fluctuated in the     past, and we expect they <font color="blue">will fluctuate</font> in the future as a result of many     factors, some of which are outside of our control</td>
    </tr>
    <tr>
      <td>In addition, we <font color="blue">manufacture</font> our products <font color="blue">based on</font> forecasted orders rather     <font color="blue">than on outstanding orders</font></td>
    </tr>
    <tr>
      <td>Accordingly, our <font color="blue">expense levels</font> are based, in     part, on expected <font color="blue">future sales</font>, and we <font color="blue">generally</font> cannot quickly adjust     operating expenses</td>
    </tr>
    <tr>
      <td>For example, research and <font color="blue">development</font> and general and     <font color="blue">administrative expenses</font> are not <font color="blue">directly affected by variations</font> in revenues</td>
    </tr>
    <tr>
      <td>As  a  result,  if  sales  levels  in a <font color="blue">particular quarter</font> do not meet     <font color="blue">expectations</font>,  we  may  not  be able to adjust operating expenses in a     <font color="blue">sufficient timeframe</font> to compensate for the shortfall, and our results of     <font color="blue">operations</font>  for  that  quarter  may be <font color="blue">seriously harmed</font></td>
    </tr>
    <tr>
      <td>Likewise, our     <font color="blue">manufacturing</font> processes may in <font color="blue">certain instances</font> create a risk of excess or     inadequate <font color="blue">inventory levels</font> if orders do not <font color="blue">match forecasts</font></td>
    </tr>
    <tr>
      <td>Due to the <font color="blue">preceding factors</font>, we may experience a shortfall in revenues or     earnings or <font color="blue">otherwise fail</font> to meet public market <font color="blue">expectations</font>, <font color="blue">which could</font>     <font color="blue">materially</font> and <font color="blue">adversely</font> affect our business, <font color="blue">financial condition</font>, results     of <font color="blue">operations</font> and the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Because our revenues     and  operating  results  are  <font color="blue">difficult</font>  to  predict,  we believe that     period-to-period comparisons of our results of <font color="blue">operations</font> are not a good     <font color="blue">indication</font> of our <font color="blue">future performance</font></td>
    </tr>
    <tr>
      <td><font color="blue">Failure  </font>to  maintain  <font color="blue">effective</font>  internal controls in <font color="blue">accordance</font> with     Section 404 of the Sarbanes-Oxley Act of 2002 could have a material adverse     effect on our stock price</td>
    </tr>
    <tr>
      <td>Section 404 of the Sarbanes-Oxley Act of 2002 and the related rules and     <font color="blue">regulations</font>  of  the  SEC require annual <font color="blue">management</font> <font color="blue"><font color="blue">assessment</font>s</font> of the     <font color="blue">effective</font>ness of our <font color="blue">internal control over financial</font> reporting and a report     by  our <font color="blue">independent registered public</font> <font color="blue">accounting</font> firm attesting to and     reporting on these <font color="blue"><font color="blue">assessment</font>s</font></td>
    </tr>
    <tr>
      <td>If we fail to maintain the adequacy of our     <font color="blue">internal control over financial</font> reporting, <font color="blue">as such standards</font> are modified,     supplemented or <font color="blue">amended from</font> time to time, we may not be able to ensure that     we can conclude on an <font color="blue">ongoing basis</font> that we have <font color="blue">effective</font> internal control     over  financial  reporting  in  <font color="blue">accordance</font>  with  Section 404  of  the     Sarbanes-Oxley Act of 2002 and the related rules and <font color="blue">regulations</font> of the SEC     If  we  cannot  <font color="blue">favorably assess</font>, or our <font color="blue">independent registered public</font>     <font color="blue">accounting</font> firm is unable to provide an <font color="blue">unqualified attestation</font> report on     our <font color="blue">assessment</font> of, the <font color="blue">effective</font>ness of our <font color="blue">internal control over financial</font>     reporting, <font color="blue">investor confidence</font> in the re<font color="blue">liability</font> of our financial reports     may be <font color="blue">adversely</font> affected, <font color="blue">which could</font> have a material adverse effect on our     stock price</td>
    </tr>
    <tr>
      <td>20       _________________________________________________________________    [86]Table of <font color="blue">Contents       </font>Our  stock price is volatile, <font color="blue">which could</font> cause <font color="blue">stockholders</font> to lose a     substantial part of their <font color="blue">investment</font> in our stock</td>
    </tr>
    <tr>
      <td>The <font color="blue">stock market</font> in general, and the <font color="blue">stock prices</font> of <font color="blue">technology</font> companies in     particular,  have recently experienced <font color="blue">volatility</font> which has often been     unrelated  to  the  operating performance of any <font color="blue">particular company</font> or     companies</td>
    </tr>
    <tr>
      <td>In the twelve months ended <font color="blue">December </font>31, 2005, the closing sales     price of our <font color="blue">common stock</font> ranged from dlra18dtta16 to dlra28dtta93</td>
    </tr>
    <tr>
      <td>Our stock price     could  decline  <font color="blue">regardless</font>  of  our  actual operating performance, and     <font color="blue">stockholders</font> could lose a substantial part of their <font color="blue">investment</font> as a result     of industry or market-based <font color="blue">fluctuations</font></td>
    </tr>
    <tr>
      <td>In the past, our stock has traded     <font color="blue">relatively</font> thinly</td>
    </tr>
    <tr>
      <td>If a more active public market for our stock is not     sustained, it may be <font color="blue">difficult</font> for <font color="blue">stockholders</font> to resell shares of our     <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Because we do not anticipate <font color="blue">paying cash dividends on</font> our     <font color="blue">common stock</font> for the foreseeable future, <font color="blue">stockholders</font> will not be able to     receive a return on their <font color="blue">shares unless</font> they sell them</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of our <font color="blue">common stock</font> will likely fluctuate in response to a     number of factors, including the following:         •  domestic and <font color="blue">international</font> economic, business and <font color="blue">political conditions</font>;         •  <font color="blue">economic conditions within</font> the <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font>     <font color="blue">industries</font>;          •  our failure to meet our performance estimates or the performance     estimates of <font color="blue">securities analysts</font>;         •  changes in financial estimates of our revenues and operating results by     us or <font color="blue">securities analysts</font>;         •  changes in buy/sell recommendations by <font color="blue">securities analysts</font>; and         •  the timing of <font color="blue">announcements</font> by us or our <font color="blue"><font color="blue">competitor</font>s</font> of <font color="blue">significant</font>     products,  contracts  or <font color="blue"><font color="blue">acquisition</font>s</font> or publicity regarding actual or     potential results or <font color="blue">performance thereof</font></td>
    </tr>
    <tr>
      <td><font color="blue">Provisions </font>of our charter <font color="blue">documents</font> <font color="blue">and Delaware </font><font color="blue">law may inhibit</font> a takeover,     <font color="blue">which could</font> limit the <font color="blue">price investors might</font> be willing to pay in the future     for our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td><font color="blue">Provisions </font>in our <font color="blue">certificate</font> of <font color="blue">incorporation</font> and bylaws may have the     effect of delaying or preventing an <font color="blue">acquisition</font> or merger in which we are     not the surviving company or which results in changes in our <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>For     example, our <font color="blue">certificate</font> of <font color="blue">incorporation</font> gives our <font color="blue">Board of Directors </font>the     authority to issue shares of <font color="blue">preferred stock</font> and to determine the price,     rights,  <font color="blue">preferences</font> and privileges and <font color="blue">restrictions</font>, including voting     rights,  of  those  shares  without  any <font color="blue">further vote</font> or <font color="blue">action by</font> our     <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>The rights of the holders of <font color="blue">common stock</font> will be subject to,     and may be <font color="blue">harmed by</font>, the rights of the holders of any shares of preferred     stock that may be issued in the future</td>
    </tr>
    <tr>
      <td>The issuance of <font color="blue">preferred stock</font> may     delay, defer or prevent a change in control, as the terms of the preferred     stock that might be <font color="blue">issued could potentially prohibit</font> our <font color="blue">consummation</font> of     any  merger,  reorganization, sale of <font color="blue">substantially</font> all of our assets,     <font color="blue">liquidation</font>  or  other <font color="blue">extraordinary corporate transaction without</font> the     approval of the holders of the <font color="blue">outstanding shares</font> of <font color="blue">preferred stock</font></td>
    </tr>
    <tr>
      <td>The     issuance  of  <font color="blue">preferred stock</font> could also have a dilutive effect on our     <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>In addition, because we are <font color="blue">incorporated</font> in Delaware, we are     governed  by  the  provisions  of  Section 203 of the Delaware General     Corporation  Law</td>
    </tr>
    <tr>
      <td>These <font color="blue">provisions may prohibit</font> large <font color="blue">stockholders</font>, in     particular those owning 15prca or more of the outstanding voting stock, from     <font color="blue">consummating</font> a merger or <font color="blue">combination</font> involving us</td>
    </tr>
    <tr>
      <td>Further, in October 2001,     our <font color="blue">Board of Directors </font>adopted a <font color="blue">stockholder rights</font> plan, <font color="blue">commonly known as</font>     a “<font color="blue">poison pill</font></td>
    </tr>
    <tr>
      <td>” These <font color="blue">provisions described</font> above and our <font color="blue">poison pill</font> could     limit the price that investors might be willing to pay in the future for our     <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Our actual results could differ <font color="blue">materially</font> from those anticipated in our     forward-looking statements</td>
    </tr>
    <tr>
      <td>This report contains forward-looking statements within the meaning of the     <font color="blue">federal securities laws</font> that relate to <font color="blue">future events</font> or our <font color="blue">future financial</font>     performance</td>
    </tr>
    <tr>
      <td>When used in this report, you can identify forward-looking     statements  <font color="blue">by terminology such as</font> “believes,” “anticipates,” “plans,”     “predicts,” “expects,” “estimates,” “intends,” “will,” “continue,” “may,”     “potential,” “should” and similar <font color="blue">expressions</font></td>
    </tr>
    <tr>
      <td>These statements are only     <font color="blue">predictions</font></td>
    </tr>
    <tr>
      <td>Our  actual  results  could differ <font color="blue">materially</font> from those     anticipated in our forward-looking statements as a result of many factors,     including those set forth above and elsewhere in this report</td>
    </tr>
    <tr>
      <td>21       _________________________________________________________________    [87]Table of <font color="blue">Contents       </font>Although we believe that the <font color="blue">expectations</font> reflected in our forward-looking     statements are reasonable, we <font color="blue">cannot guarantee future</font> results, levels of     activity, performance or <font color="blue">achievements</font></td>
    </tr>
    <tr>
      <td>Neither we nor any other person     assumes  <font color="blue">responsibility</font>  for  the  accuracy  and <font color="blue">completeness</font> of these     statements</td>
    </tr>
    <tr>
      <td>We  assume  no  duty to update any of the forward-looking     statements after the date of this report or to conform these statements to     actual results</td>
    </tr>
    <tr>
      <td>Accordingly, we <font color="blue">caution readers</font> not to place <font color="blue">undue reliance</font>     on these statements</td>
    </tr>
  </tbody>
</table>